Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer.
Vredenburgh JJ, Hussein A, Fisher D, Hoffman M, Elkordy M, Rubin P, Gilbert C, Kaye JA, Dykstra K, Loewy J, Peters WP. Vredenburgh JJ, et al. Biol Blood Marrow Transplant. 1998;4(3):134-41. doi: 10.1053/bbmt.1998.v4.pm9923411. Biol Blood Marrow Transplant. 1998. PMID: 9923411 Free article. Clinical Trial.
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM, Ross M, Vredenburgh J, Meisenberg B, Hars V, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Rubin P, et al. Hussein AM, et al. Eur J Haematol. 1995 May;54(5):281-7. doi: 10.1111/j.1600-0609.1995.tb00687.x. Eur J Haematol. 1995. PMID: 7781752 Corrected and republished. Clinical Trial.
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
Fisher DC, Vredenburgh JJ, Petros WP, Hussein A, Berry DA, Elkordy M, Rubin P, Gilbert CJ, Peters WP. Fisher DC, et al. Among authors: gilbert cj. Bone Marrow Transplant. 1998 Jan;21(2):117-22. doi: 10.1038/sj.bmt.1701068. Bone Marrow Transplant. 1998. PMID: 9489626 Clinical Trial.
Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Hussein AM, Ross M, Vredenburgh J, Meisenberg B, Hars V, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Rubin P, et al. Hussein AM, et al. Eur J Haematol. 1995 Nov;55(5):348-56. doi: 10.1111/j.1600-0609.1995.tb00713.x. Eur J Haematol. 1995. PMID: 7493686 Clinical Trial.
Role of cytokines in autologous bone marrow transplantation.
Peters WP, Ross M, Vredenburgh J, Hussein A, Meisenberg B, Gilbert C, Petros WP, Kurtzberg J. Peters WP, et al. Hematol Oncol Clin North Am. 1993 Jun;7(3):737-47. Hematol Oncol Clin North Am. 1993. PMID: 8344888 Review.
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. Hussein AM, et al. Cancer Chemother Pharmacol. 1996;37(6):561-8. doi: 10.1007/s002800050429. Cancer Chemother Pharmacol. 1996. PMID: 8612310 Clinical Trial.
62 results